Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15043376 | 1.00 | CYP2D6 (0.41) | CYP2D6MEN1RECQLKMT2AIDO1 | |
| SCHEMBL14208065 | 0.79 | DRD2 (0.38) | CYP2D6MEN1RECQLKMT2AADRA1A | |
| SCHEMBL6109896 | 0.79 | DRD2 (0.45) | — | |
| SCHEMBL6109893 | 0.79 | DRD2 (0.45) | — | |
| SCHEMBL14202528 | 0.78 | CYP2D6 (0.38) | CYP2D6MEN1RECQLKMT2AIDO1 | |
| SCHEMBL14458459 | 0.74 | CHRNB2 (0.39) | MEN1KMT2APLAUL3MBTL1CHRNB2 | |
| SCHEMBL5621945 | 0.74 | CHRNB2 (0.39) | MEN1KMT2APLAUL3MBTL1CHRNB2 | |
| SCHEMBL11221034 | 0.74 | DRD2 (0.49) | MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL11221031 | 0.74 | DRD2 (0.49) | MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL6107223 | 0.71 | PNMT (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1496898-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2008-05-28 | — | — | EP | disclosed |
| US-7365196-B2 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK SHARP & DOHME LTD. (GB) | 2008-04-29 | — | — | US | disclosed |
| US-7365196-B2 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK SHARP & DOHME LTD. (GB) | 2008-04-29 | — | — | US | disclosed |
| US-7348431-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348431-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20070173525-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2007-07-26 | — | — | US | disclosed |
| US-20070173525-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2007-07-26 | — | — | US | disclosed |
| EP-1268412-B1 | SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES | MERCK SHARP & DOHME (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20060167036-A1 | Receptor or non-receptor; 5,6,7,8,9,10-hexahydro-6,9-(epiminomethano) benzo[ alpha ][8]annulenes; anticarcinogenic, antidiabetic, antiproliferative agents; autoimmune and Crohn's diseases, acromegaly, aging resistance; coadminister tamoxifen, raloxifene, taxol, trastuzumab, tirofiban or a COX-2 inhibitor | MERCK SHARP & DOHME CORP. | 2006-07-27 | — | — | US | disclosed |
| US-20040029862-A1 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK CANADA INC. (CA) | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173525-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | CYP2D6 1986/4885MEN1 2670/4885RECQL 4548/4885 |
| US-20060167036-A1 | Receptor or non-receptor; 5,6,7,8,9,10-hexahydro-6,9-(epiminomethano) benzo[ alpha ][8]annulenes; anticarcinogenic, antidiabetic, antiproliferative agents; autoimmune and Crohn's diseases, acromegaly, aging resistance; coadminister tamoxifen, raloxifene, taxol, trastuzumab, tirofiban or a COX-2 inhibitor | IGF1R, ERBB2, TSHR | CYP2D6 1530/4885MEN1 2022/4885RECQL 4294/4885 |
| US-20040029862-A1 | Sulphonamido-substituted bridged bicycloalkyl derivatives | BACE1, BACE2, PSEN2 | CYP2D6 2858/4885MEN1 4589/4885RECQL 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.